Sutro Biopharma (NASDAQ:STRO)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Monday, AnalystRatings.com reports. They presently have a $18.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 73.58% from the company’s current price.
STRO has been the topic of several other reports. Zacks Investment Research lowered Sutro Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, August 17th. JMP Securities restated a “market outperform” rating and set a $16.00 target price on shares of Sutro Biopharma in a report on Thursday, September 5th. Deutsche Bank began coverage on Sutro Biopharma in a report on Thursday, July 18th. They set a “buy” rating and a $22.00 target price on the stock. ValuEngine upgraded Sutro Biopharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, BTIG Research began coverage on Sutro Biopharma in a report on Monday, October 7th. They set a “buy” rating and a $19.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $19.40.
NASDAQ STRO opened at $10.37 on Monday. Sutro Biopharma has a fifty-two week low of $7.69 and a fifty-two week high of $14.75. The stock’s 50-day moving average is $9.61 and its two-hundred day moving average is $10.42. The firm has a market cap of $230.44 million and a P/E ratio of -1.69.
Sutro Biopharma (NASDAQ:STRO) last posted its earnings results on Wednesday, August 14th. The company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.05). The business had revenue of $10.53 million during the quarter, compared to the consensus estimate of $8.38 million. On average, analysts forecast that Sutro Biopharma will post -2.51 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of STRO. Creative Planning bought a new stake in shares of Sutro Biopharma in the 2nd quarter worth approximately $359,000. Jennison Associates LLC lifted its holdings in shares of Sutro Biopharma by 15.3% in the 2nd quarter. Jennison Associates LLC now owns 158,874 shares of the company’s stock worth $1,808,000 after purchasing an additional 21,086 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Sutro Biopharma by 240.7% in the 2nd quarter. Wells Fargo & Company MN now owns 11,484 shares of the company’s stock worth $130,000 after purchasing an additional 8,113 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Sutro Biopharma by 1,365.7% in the 2nd quarter. Acadian Asset Management LLC now owns 9,058 shares of the company’s stock worth $103,000 after purchasing an additional 8,440 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Sutro Biopharma by 72.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 22,592 shares of the company’s stock worth $258,000 after purchasing an additional 9,482 shares during the last quarter. Institutional investors and hedge funds own 51.18% of the company’s stock.
About Sutro Biopharma
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
Further Reading: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.